FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914853315> ?p ?o ?g. }

• W2914853315 abstract "Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate in people with JME. This is an update of a Cochrane Review first published in 2015, and last updated in 2017.To evaluate the efficacy and tolerability of topiramate in the treatment of JME.For the latest update, on 10 July 2018 we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid 1946- ), and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies.We included randomized controlled trials (RCTs) investigating topiramate versus placebo or other AED treatment for people with JME, with the outcomes of proportion of responders and proportion of participants experiencing adverse events (AEs).Two review authors independently screened the titles and abstracts of identified records, selected studies for inclusion, extracted data, cross-checked the data for accuracy and assessed the methodological quality. We performed no meta-analyses due to the limited available data.We included three studies with a total of 83 participants. For efficacy, a greater proportion of participants in the topiramate group had a 50% or more reduction in primarily generalized tonic-clonic seizures (PGTCS) compared with participants in the placebo group. There were no significant differences between topiramate and valproate in participants responding with a 50% or more reduction in myoclonic seizures or in PGTCS, or becoming seizure-free. Concerning tolerability, we ranked AEs associated with topiramate as moderate to severe, while we ranked 59% of AEs linked to valproate as severe complaints. Moreover, systemic toxicity scores were higher in the valproate group than the topiramate group.Overall we judged all three studies to be at high risk of attrition bias and at unclear risk of reporting bias. We judged all three studies to be at low to unclear bias for the remaining risk of bias domains (random sequence, allocation, blinding). We judged the quality of the evidence from the studies to be very low.We have found no new studies since the last version of this review was published in 2017. This review does not provide sufficient evidence to support topiramate for the treatment of people with JME. Based on the current limited available data, topiramate seems to be better tolerated than valproate, but has no clear benefits over valproate in terms of efficacy. Well-designed, double-blind RCTs with large samples are required to test the efficacy and tolerability of topiramate in people with JME." @default.
• W2914853315 created "2019-02-21" @default.
• W2914853315 creator A5013938837 @default.
• W2914853315 creator A5023893251 @default.
• W2914853315 creator A5057117256 @default.
• W2914853315 date "2019-01-28" @default.
• W2914853315 modified "2023-10-11" @default.
• W2914853315 title "Topiramate for juvenile myoclonic epilepsy" @default.
• W2914853315 cites W1584035225 @default.
• W2914853315 cites W1967170548 @default.
• W2914853315 cites W1973491611 @default.
• W2914853315 cites W1976364205 @default.
• W2914853315 cites W1986836611 @default.
• W2914853315 cites W1995647300 @default.
• W2914853315 cites W1998338808 @default.
• W2914853315 cites W2006373091 @default.
• W2914853315 cites W2006821779 @default.
• W2914853315 cites W2026750272 @default.
• W2914853315 cites W2046391772 @default.
• W2914853315 cites W2092270366 @default.
• W2914853315 cites W2093392404 @default.
• W2914853315 cites W2113548968 @default.
• W2914853315 cites W2125435699 @default.
• W2914853315 cites W2125585557 @default.
• W2914853315 cites W2130235475 @default.
• W2914853315 cites W2144520245 @default.
• W2914853315 cites W2162869409 @default.
• W2914853315 cites W2171903235 @default.
• W2914853315 cites W3163604245 @default.
• W2914853315 cites W4237847849 @default.
• W2914853315 cites W4245821474 @default.
• W2914853315 cites W4295332804 @default.
• W2914853315 doi "https://doi.org/10.1002/14651858.cd010008.pub4" @default.
• W2914853315 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8612308" @default.
• W2914853315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34817852" @default.
• W2914853315 hasPublicationYear "2019" @default.
• W2914853315 type Work @default.
• W2914853315 sameAs 2914853315 @default.
• W2914853315 citedByCount "9" @default.
• W2914853315 countsByYear W29148533152020 @default.
• W2914853315 countsByYear W29148533152021 @default.
• W2914853315 countsByYear W29148533152022 @default.
• W2914853315 countsByYear W29148533152023 @default.
• W2914853315 crossrefType "journal-article" @default.
• W2914853315 hasAuthorship W2914853315A5013938837 @default.
• W2914853315 hasAuthorship W2914853315A5023893251 @default.
• W2914853315 hasAuthorship W2914853315A5057117256 @default.
• W2914853315 hasBestOaLocation W29148533152 @default.
• W2914853315 hasConcept C118552586 @default.
• W2914853315 hasConcept C126322002 @default.
• W2914853315 hasConcept C142724271 @default.
• W2914853315 hasConcept C168563851 @default.
• W2914853315 hasConcept C187212893 @default.
• W2914853315 hasConcept C197934379 @default.
• W2914853315 hasConcept C204787440 @default.
• W2914853315 hasConcept C27081682 @default.
• W2914853315 hasConcept C2777683783 @default.
• W2914853315 hasConcept C2778186239 @default.
• W2914853315 hasConcept C2778375690 @default.
• W2914853315 hasConcept C2779814861 @default.
• W2914853315 hasConcept C71924100 @default.
• W2914853315 hasConcept C95190672 @default.
• W2914853315 hasConceptScore W2914853315C118552586 @default.
• W2914853315 hasConceptScore W2914853315C126322002 @default.
• W2914853315 hasConceptScore W2914853315C142724271 @default.
• W2914853315 hasConceptScore W2914853315C168563851 @default.
• W2914853315 hasConceptScore W2914853315C187212893 @default.
• W2914853315 hasConceptScore W2914853315C197934379 @default.
• W2914853315 hasConceptScore W2914853315C204787440 @default.
• W2914853315 hasConceptScore W2914853315C27081682 @default.
• W2914853315 hasConceptScore W2914853315C2777683783 @default.
• W2914853315 hasConceptScore W2914853315C2778186239 @default.
• W2914853315 hasConceptScore W2914853315C2778375690 @default.
• W2914853315 hasConceptScore W2914853315C2779814861 @default.
• W2914853315 hasConceptScore W2914853315C71924100 @default.
• W2914853315 hasConceptScore W2914853315C95190672 @default.
• W2914853315 hasIssue "1" @default.
• W2914853315 hasLocation W29148533151 @default.
• W2914853315 hasLocation W29148533152 @default.
• W2914853315 hasLocation W29148533153 @default.
• W2914853315 hasLocation W29148533154 @default.
• W2914853315 hasOpenAccess W2914853315 @default.
• W2914853315 hasPrimaryLocation W29148533151 @default.
• W2914853315 hasRelatedWork W1584035225 @default.
• W2914853315 hasRelatedWork W1964990613 @default.
• W2914853315 hasRelatedWork W1973308362 @default.
• W2914853315 hasRelatedWork W2012254833 @default.
• W2914853315 hasRelatedWork W2125585557 @default.
• W2914853315 hasRelatedWork W2168508835 @default.
• W2914853315 hasRelatedWork W2353505721 @default.
• W2914853315 hasRelatedWork W2914853315 @default.
• W2914853315 hasRelatedWork W3094084700 @default.
• W2914853315 hasRelatedWork W60061256 @default.
• W2914853315 hasVolume "2019" @default.
• W2914853315 isParatext "false" @default.
• W2914853315 isRetracted "false" @default.
• W2914853315 magId "2914853315" @default.
• W2914853315 workType "article" @default.